ATNM
Actinium Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.98
-0.02 (-2.00%)
Current Price
| Previous Close | $1.00 |
| Open | $1.02 |
| Day High | $1.02 |
| Day Low | $0.98 |
| Volume | 219,453 |
Stock Information
| Shares Outstanding | 31.37M |
| Total Debt | $1.52M |
| Cash Equivalents | $42.13M |
| Revenue | $90K |
| Net Income | $-23.47M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $30.75M |
| EPS (TTM) | $-0.76 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-9.87M |
| Sales | $90K |
| Income | $-23.47M |
| Book/sh | $0.07 |
| Cash/sh | $1.34 |
| Employees | 25 |
Financial Ratios
| Quick Ratio | 5.73 |
| Current Ratio | 5.89 |
| Debt/Eq | 65.93 |
Returns & Margins
| ROA | -27.95% |
| ROE | -167.66% |
| Gross Margin | 100.00% |
| Operating Margin | -28346.67% |
Ownership
| Insider Ownership | 2.35% |
| Institutional Ownership | 20.61% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.80 |
| P/S | 341.64 |
| P/B | 13.42 |
Analyst Data
| Recommendation | buy |
| Target Price | $5.00 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 33.93 |
| ATR | nan |
| Shares Float | 31.04M |
| Short Float | 3.47% |
| Short Ratio | 9.99 |
| Volatility | -0.05 |
| Rel Volume | 1.59 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $nan | 219,453 |
| 2026-06-15 | $1.00 | 101,600 |
| 2026-06-12 | $1.01 | 199,200 |
| 2026-06-11 | $1.04 | 134,200 |
| 2026-06-10 | $1.05 | 151,200 |
| 2026-06-09 | $1.01 | 136,900 |
| 2026-06-08 | $1.06 | 158,900 |
| 2026-06-05 | $1.08 | 197,100 |
| 2026-06-04 | $1.11 | 288,800 |
| 2026-06-03 | $1.16 | 232,400 |
| 2026-06-02 | $1.22 | 84,600 |
| 2026-06-01 | $1.18 | 93,800 |
| 2026-05-29 | $1.26 | 184,600 |
| 2026-05-28 | $1.15 | 110,100 |
| 2026-05-27 | $1.18 | 103,500 |
| 2026-05-26 | $1.16 | 79,200 |
| 2026-05-22 | $1.18 | 73,200 |
| 2026-05-21 | $1.18 | 79,700 |
| 2026-05-20 | $1.17 | 78,800 |
| 2026-05-19 | $1.15 | 57,600 |
| 2026-05-18 | $1.17 | 105,700 |
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
đ° Latest News
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?
Zacks âĸ 2025-12-22T14:40:03Z
Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
Zacks âĸ 2025-12-05T14:40:03Z
Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-11-19T14:41:02Z
Actinium: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-14T22:01:04ZSector Update: Health Care Stocks Advance Monday Afternoon
MT Newswires âĸ 2025-10-13T17:42:30ZIs Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-09-18T13:40:02Z
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-09-02T13:40:02Z
Actinium: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-08T21:15:00ZActinium Highlights ATNM 400 Progress at SNMMI Conference
Insider Monkey âĸ 2025-07-03T02:05:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $90,000 | $0 | $81,000 | $1,030,000 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $36,337,000 | $42,121,000 | $52,001,000 | $35,134,000 |
| Net Non Operating Interest Income Expense | $2,360,000 | $3,878,000 | $3,102,000 | $1,087,000 |
| Operating Expense | $36,337,000 | $42,121,000 | $52,001,000 | $35,134,000 |
| General And Administrative Expense | $15,213,000 | $12,076,000 | $13,331,000 | $11,999,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Net Interest Income | $2,360,000 | $3,878,000 | $3,102,000 | $1,087,000 |
| Interest Income | $2,360,000 | $3,878,000 | $3,102,000 | $1,087,000 |
| Normalized Income | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Net Income From Continuing And Discontinued Operation | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Total Operating Income As Reported | $-36,247,000 | $-42,121,000 | $-51,920,000 | $-34,104,000 |
| Net Income Common Stockholders | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Net Income | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Net Income Including Noncontrolling Interests | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Net Income Continuous Operations | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Pretax Income | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Interest Income Non Operating | $2,360,000 | $3,878,000 | $3,102,000 | $1,087,000 |
| Operating Income | $-36,247,000 | $-42,121,000 | $-51,920,000 | $-34,104,000 |
| Per Share | ||||
| Diluted EPS | $-1.09 | $-1.27 | $-1.83 | $-1.37 |
| Basic EPS | $-1.09 | $-1.27 | $-1.83 | $-1.37 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-35,426,000 | $-41,310,000 | $-51,130,000 | $-33,405,000 |
| Reconciled Depreciation | $821,000 | $811,000 | $790,000 | $699,000 |
| EBITDA (Bullshit earnings) | $-35,426,000 | $-41,310,000 | $-51,130,000 | $-33,405,000 |
| EBIT | $-36,247,000 | $-42,121,000 | $-51,920,000 | $-34,104,000 |
| Diluted Average Shares | $31,195,891 | $30,070,028 | $26,604,045 | $24,141,545 |
| Basic Average Shares | $31,195,891 | $30,070,028 | $26,604,045 | $24,141,545 |
| Diluted NI Availto Com Stockholders | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Research And Development | $21,124,000 | $30,045,000 | $38,670,000 | $23,135,000 |
| Selling General And Administration | $15,213,000 | $12,076,000 | $13,331,000 | $11,999,000 |
| Other Gand A | $15,213,000 | $12,076,000 | $13,331,000 | $11,999,000 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,834,000 | $32,758,000 | $36,379,000 | $66,481,000 |
| Total Assets | $51,775,000 | $76,899,000 | $81,445,000 | $114,192,000 |
| Total Non Current Assets | $2,394,000 | $2,393,000 | $3,182,000 | $3,250,000 |
| Other Non Current Assets | $335,000 | $324,000 | $313,000 | $302,000 |
| Current Assets | $49,381,000 | $74,506,000 | $78,263,000 | $110,942,000 |
| Other Current Assets | $168,000 | $357,000 | $226,000 | $65,000 |
| Prepaid Assets | $1,215,000 | $1,245,000 | $1,360,000 | $1,571,000 |
| Cash Cash Equivalents And Short Term Investments | $47,998,000 | $72,904,000 | $76,677,000 | $108,910,000 |
| Cash And Cash Equivalents | $47,998,000 | $72,904,000 | $76,677,000 | $108,910,000 |
| Restricted Cash | - | - | $0 | $396,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,694,000 | $1,573,000 | $2,113,000 | $2,581,000 |
| Long Term Debt And Capital Lease Obligation | $972,000 | $993,000 | $1,572,000 | $2,083,000 |
| Current Debt And Capital Lease Obligation | $722,000 | $580,000 | $541,000 | $498,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $43,941,000 | $44,141,000 | $45,066,000 | $47,711,000 |
| Total Non Current Liabilities Net Minority Interest | $35,972,000 | $35,993,000 | $36,572,000 | $37,083,000 |
| Non Current Deferred Liabilities | $35,000,000 | $35,000,000 | $35,000,000 | $35,000,000 |
| Current Liabilities | $7,969,000 | $8,148,000 | $8,494,000 | $10,628,000 |
| Payables And Accrued Expenses | $7,247,000 | $7,568,000 | $7,953,000 | $10,130,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $7,834,000 | $32,758,000 | $36,379,000 | $66,481,000 |
| Total Equity Gross Minority Interest | $7,834,000 | $32,758,000 | $36,379,000 | $66,481,000 |
| Stockholders Equity | $7,834,000 | $32,758,000 | $36,379,000 | $66,481,000 |
| Gains Losses Not Affecting Retained Earnings | $-20,000 | $0 | - | - |
| Other Equity Adjustments | $-20,000 | - | - | - |
| Retained Earnings | $-409,713,000 | $-375,826,000 | $-337,583,000 | $-288,765,000 |
| Other | ||||
| Ordinary Shares Number | $31,195,891 | $31,195,891 | $27,634,213 | $25,674,823 |
| Share Issued | $31,195,891 | $31,195,891 | $27,634,213 | $25,674,823 |
| Tangible Book Value | $7,834,000 | $32,758,000 | $36,379,000 | $66,481,000 |
| Invested Capital | $7,834,000 | $32,758,000 | $36,379,000 | $66,481,000 |
| Working Capital | $41,412,000 | $66,358,000 | $69,769,000 | $100,314,000 |
| Capital Lease Obligations | $1,694,000 | $1,573,000 | $2,113,000 | $2,581,000 |
| Total Capitalization | $7,834,000 | $32,758,000 | $36,379,000 | $66,481,000 |
| Additional Paid In Capital | $417,536,000 | $408,553,000 | $373,934,000 | $355,220,000 |
| Capital Stock | $31,000 | $31,000 | $28,000 | $26,000 |
| Common Stock | $31,000 | $31,000 | $28,000 | $26,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $35,000,000 | $35,000,000 | $35,000,000 | $35,000,000 |
| Long Term Capital Lease Obligation | $972,000 | $993,000 | $1,572,000 | $2,083,000 |
| Current Capital Lease Obligation | $722,000 | $580,000 | $541,000 | $498,000 |
| Net PPE | $2,059,000 | $2,069,000 | $2,869,000 | $2,948,000 |
| Accumulated Depreciation | $-1,064,000 | $-891,000 | $-694,000 | $-487,000 |
| Gross PPE | $3,123,000 | $2,960,000 | $3,563,000 | $3,435,000 |
| Construction In Progress | $104,000 | $0 | - | - |
| Other Properties | $2,581,000 | $2,522,000 | $3,125,000 | $3,120,000 |
| Machinery Furniture Equipment | $438,000 | $438,000 | $438,000 | $315,000 |
| Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-24,684,000 | $-33,083,000 | $-47,488,000 | $8,278,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-24,580,000 | $-33,072,000 | $-47,335,000 | $8,644,000 |
| Cash Flow From Continuing Operating Activities | $-24,580,000 | $-33,072,000 | $-47,335,000 | $8,644,000 |
| Investing Activities | ||||
| Capital Expenditure | $-104,000 | $-11,000 | $-153,000 | $-366,000 |
| Investing Cash Flow | $-104,000 | $-11,000 | $-153,000 | $-366,000 |
| Cash Flow From Continuing Investing Activities | $-104,000 | $-11,000 | $-153,000 | $-366,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $29,255,000 | $14,612,000 | $23,158,000 |
| Financing Cash Flow | $-217,000 | $29,321,000 | $14,870,000 | $23,109,000 |
| Cash Flow From Continuing Financing Activities | $-217,000 | $29,321,000 | $14,870,000 | $23,109,000 |
| Net Other Financing Charges | $-207,000 | - | - | - |
| Net Common Stock Issuance | $0 | $29,255,000 | $14,612,000 | $23,158,000 |
| Common Stock Issuance | $0 | $29,255,000 | $14,612,000 | $23,158,000 |
| Other | ||||
| Repayment Of Debt | $-10,000 | $-9,000 | $-4,000 | $-49,000 |
| End Cash Position | $48,333,000 | $73,228,000 | $76,990,000 | $109,608,000 |
| Beginning Cash Position | $73,228,000 | $76,990,000 | $109,608,000 | $78,221,000 |
| Effect Of Exchange Rate Changes | $6,000 | $0 | - | - |
| Changes In Cash | $-24,901,000 | $-3,762,000 | $-32,618,000 | $31,387,000 |
| Proceeds From Stock Option Exercised | $0 | $75,000 | $262,000 | $0 |
| Net Issuance Payments Of Debt | $-10,000 | $-9,000 | $-4,000 | $-49,000 |
| Net Long Term Debt Issuance | $-10,000 | $-9,000 | $-4,000 | $-49,000 |
| Long Term Debt Payments | $-10,000 | $-9,000 | $-4,000 | $-49,000 |
| Net PPE Purchase And Sale | $-104,000 | $-11,000 | $-153,000 | $-366,000 |
| Purchase Of PPE | $-104,000 | $-11,000 | $-153,000 | $-366,000 |
| Change In Working Capital | $-704,000 | $-932,000 | $-3,149,000 | $38,167,000 |
| Change In Other Current Liabilities | $-577,000 | $-530,000 | $-494,000 | $-272,000 |
| Change In Payables And Accrued Expense | $-346,000 | $-387,000 | $-2,177,000 | $4,595,000 |
| Change In Prepaid Assets | $219,000 | $-15,000 | $49,000 | $-158,000 |
| Stock Based Compensation | $9,190,000 | $5,292,000 | $3,842,000 | $2,795,000 |
| Depreciation Amortization Depletion | $821,000 | $811,000 | $790,000 | $699,000 |
| Depreciation And Amortization | $821,000 | $811,000 | $790,000 | $699,000 |
| Depreciation | $821,000 | $811,000 | $790,000 | - |
| Net Income From Continuing Operations | $-33,887,000 | $-38,243,000 | $-48,818,000 | $-33,017,000 |
| Interest Paid Supplemental Data | - | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | - | $0 | $0 | $0 |
| Change In Other Current Assets | - | $0 | $-527,000 | $0 |
| Change In Other Working Capital | - | - | - | $34,002,000 |
Fetched: 2026-06-17